Home Ophthalmology Blog Retina Weight-Loss Medicines, Bariatric Surgery and the Eye: GLP-1 Drugs, Diabetic Retinopathy, NAION, IIH and Vitamin Deficiency
Weight-Loss Medicines, Bariatric Surgery and the Eye: GLP-1 Drugs, Diabetic Retinopathy, NAION, IIH and Vitamin Deficiency
Last updated: November 2026
Key points in 60 seconds
GLP-1 receptor agonists (semaglutide, liraglutide) and tirzepatide are now widely used for diabetes and obesity, so eye clinics see many patients taking them.
Rapid falls in HbA1c can cause early worsening of diabetic retinopathy; examine the retina before starting and follow closely in the first year if retinopathy is present.
Semaglutide has been linked to NAION; the European Medicines Agency lists it as a very rare side effect.
In idiopathic intracranial hypertension, weight loss is disease-modifying; bariatric surgery and GLP-1 drugs both have trial evidence.
After bariatric surgery, look for vitamin A deficiency (night blindness, xerophthalmia), and also B1, B12 and copper deficiency causing ocular motor or optic nerve problems.
"I have started weekly injections for weight loss. Will they affect my eyes?" Eye doctors now hear this every week. The answer depends on the patient: a person with diabetic retinopathy, a young woman with papilloedema, a man with a crowded disc, and a patient years after gastric bypass each face a different eye issue.
The medicines in brief
Medicine
Type
Eye points
Semaglutide (weekly injection, also oral)
GLP-1 receptor agonist
Early worsening of diabetic retinopathy; NAION signal
Liraglutide, dulaglutide, exenatide
GLP-1 receptor agonists
Class effects on glucose; exenatide studied in IIH
Tirzepatide
Dual GIP and GLP-1 receptor agonist
Large weight loss; retinal data still accumulating
Newer agents (oral small-molecule GLP-1 agonists such as orforglipron; triple agonists such as retatrutide; amylin combinations)
In late trials or recently approved
Eye safety data still limited
Phentermine-topiramate
Appetite suppressant plus anticonvulsant
Topiramate: acute bilateral angle closure and myopic shift; phentermine: mydriasis
Orlistat
Lipase inhibitor
Malabsorption of fat-soluble vitamins, including vitamin A
Metformin
Biguanide
Long-term use can lower vitamin B12
Diabetic retinopathy: early worsening
In the SUSTAIN-6 trial, semaglutide was associated with more retinopathy complications than placebo, mostly in patients who already had retinopathy and whose HbA1c fell quickly. The same "early worsening" was seen decades ago with intensive insulin therapy in the DCCT and is thought to reflect the speed of glucose lowering rather than a direct toxic effect. Long-term, better glucose control protects the retina. The FOCUS trial is studying the effect of semaglutide on retinopathy directly.
Practical approach
Ask every diabetic patient about GLP-1 or tirzepatide treatment, and when it started.
Examine the retina (with OCT if possible) before or soon after starting, especially if HbA1c is high or retinopathy is known.
If there is moderate or worse non-proliferative retinopathy, proliferative retinopathy or macular oedema, review every 3 to 4 months in the first year.
Treat sight-threatening disease as usual. Do not ask the physician to stop the drug without good reason; discuss a slower reduction in HbA1c if retinopathy is advanced.
Expect temporary changes in refraction while glucose is changing; delay new spectacles until it is stable.
NAION
Observational studies since 2024 have reported a higher rate of non-arteritic anterior ischaemic optic neuropathy in people taking semaglutide, and in 2025 the European Medicines Agency concluded that NAION is a very rare side effect of semaglutide medicines (up to 1 in 10,000 people). Patients with a crowded disc, sleep apnoea or previous NAION in one eye may deserve a discussion with their physician. The details are in semaglutide and NAION.
Idiopathic intracranial hypertension
Weight gain is a major risk factor, and weight loss of around 5 to 15% often brings remission.
The IIH:WT trial showed that bariatric surgery lowered intracranial pressure more than a community weight-management programme, with the effect lasting at two years.
GLP-1 receptor agonists reduce CSF secretion in laboratory studies; exenatide lowered ICP in a small trial, and observational studies of semaglutide and tirzepatide in IIH are encouraging.
Weight loss is a long-term plan. It does not replace urgent treatment (acetazolamide, CSF shunting or optic nerve sheath fenestration) when vision is threatened.
After bariatric surgery
Deficiency
Eye findings
When
Vitamin A
Night blindness, conjunctival and corneal xerosis, Bitot spots, keratomalacia; abnormal ERG; fundus flecks
Months to many years after malabsorptive operations (biliopancreatic diversion, Roux-en-Y gastric bypass), especially with poor follow-up
Often in the first months, especially with persistent vomiting
Vitamin B12
Bilateral optic neuropathy with central or centrocaecal scotomas
Years after surgery without supplements
Copper
Optic neuropathy, myeloneuropathy
Months to years; also with high zinc supplements
Vitamin E
Ophthalmoplegia, pigmentary retinopathy (rare)
Long-term malabsorption
Night blindness or dry, gritty eyes after bariatric surgery is vitamin A deficiency until proved otherwise. Check serum retinol, start replacement with the physician, and look for corneal involvement. Untreated xerophthalmia can progress to corneal melt.
Other practical points
Anaesthesia: GLP-1 drugs slow gastric emptying and may increase aspiration risk under general anaesthesia or sedation. Follow your anaesthesia department's current policy; most cataract surgery under topical or local anaesthesia is unaffected.
Refraction: fluctuating glucose with rapid weight loss changes the refraction; avoid prescribing until stable.
Topiramate: any patient on a weight-loss combination containing topiramate who develops sudden bilateral blur, myopia or eye pain needs an urgent angle assessment.
Pearls
Ask about weight-loss injections in every diabetic and every patient with a swollen or crowded disc.
Rapid HbA1c reduction plus existing retinopathy: follow closely in the first year.
Weight loss is disease-modifying in IIH; refer to weight-management services early.
Night blindness after gastric bypass: think vitamin A.
Sudden bilateral myopia and angle closure on a weight-loss pill: think topiramate.
Common mistakes
Advising patients to stop GLP-1 drugs because of early retinopathy worsening without discussing it with the physician.
Prescribing new spectacles during rapid changes in glucose.
Missing vitamin A deficiency because surgery was "many years ago".
Relying on weight loss alone when IIH is threatening vision.
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes (SUSTAIN-6). N Engl J Med. 2016;375:1834-1844
Hathaway JT, Shah MP, Hathaway DB, et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 2024;142:732-739
European Medicines Agency, PRAC. Semaglutide medicines: very rare risk of NAION. June 2025
Mollan SP, Mitchell JL, Ottridge RS, et al. Effectiveness of bariatric surgery vs community weight management intervention for the treatment of idiopathic intracranial hypertension: a randomized clinical trial. JAMA Neurol. 2021;78:678-686
Mitchell JL, Lyons HS, Walker JK, et al. The effect of GLP-1RA exenatide on idiopathic intracranial hypertension: a randomized clinical trial. Brain. 2023;146:1821-1830
Lee WB, Hamilton SM, Harris JP, Schwab IR. Ocular complications of hypovitaminosis A after bariatric surgery. Ophthalmology. 2005;112:1031-1034
Patel D. Weight-Loss Medicines, Bariatric Surgery and the Eye: GLP-1 Drugs, Diabetic Retinopathy, NAION, IIH and Vitamin Deficiency. RPC Rounds (Sadbhaav Eye Clinic). Updated November 2026. Available at: https://www.sadbhaavclinic.com/weight-loss-drugs-bariatric-surgery-eye.html. Accessed [date].
Written and medically reviewed by Dr. Dhaval Patel, MD (Ophthalmology, AIIMS New Delhi) · Editorial policy